Jose A Gómez-Puerta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1522283/publications.pdf

Version: 2024-02-01

127 papers 4,478 citations

94433 37 h-index 110387 64 g-index

137 all docs

137 docs citations

times ranked

137

3992 citing authors

#	Article	IF	CITATIONS
1	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the "CAPS Registry― Journal of Autoimmunity, 2009, 32, 240-245.	6.5	307
2	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis and Rheumatism, 2006, 54, 2568-2576.	6.7	294
3	Diagnosis and classification of the antiphospholipid syndrome. Journal of Autoimmunity, 2014, 48-49, 20-25.	6.5	238
4	Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2005, 64, 1205-1209.	0.9	209
5	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Annals of the Rheumatic Diseases, 2004, 63, 1312-1317.	0.9	161
6	The association between silica exposure and development of ANCA-associated vasculitis: Systematic review and meta-analysis. Autoimmunity Reviews, 2013, 12, 1129-1135.	5.8	135
7	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases, 2022, 81, 695-709.	0.9	130
8	Long-Term Follow-Up in 128 Patients With Primary Antiphospholipid Syndrome. Medicine (United) Tj ETQq0 0 0	rgBT/Ovei	·lock 10 Tf 50
9	Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients. Seminars in Arthritis and Rheumatism, 2006, 35, 322-332.	3.4	122
10	Racial/Ethnic Variation in Allâ€Cause Mortality Among United States Medicaid Recipients With Systemic Lupus Erythematosus: A Hispanic and Asian Paradox. Arthritis and Rheumatology, 2015, 67, 752-760.	5.6	108
11	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq1 1 0. Diseases, 2018, 77, 1549-1557.</i>	784314 rg	BT _J Overlo <mark>ck</mark>
12	Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases. Pharmacological Reviews, 2011, 63, 127-156.	16.0	95
13	Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease. Chest, 2009, 136, 1101-1111.	0.8	92
14	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Annals of the Rheumatic Diseases, 2007, 66, 740-746.	0.9	89
15	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. Autoimmunity Reviews, 2006, 6, 72-75.	5.8	83
16	Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and clinical value. Autoimmunity Reviews, 2008, 7, 606-611.	5.8	79
17	Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Annals of the Rheumatic Diseases, 2005, 64, 943-946.	0.9	74
18	Ilium Osteitis as the Main Manifestation of the SAPHO Syndrome: Response to Infliximab Therapy and Review of the Literature. Seminars in Arthritis and Rheumatism, 2008, 37, 299-306.	3.4	70

#	Article	IF	CITATIONS
19	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 1823-1831.	5.6	70
20	Anti-Neutrophil Cytoplasmic Antibody Pathogenesis in Small-Vessel Vasculitis. American Journal of Pathology, 2009, 175, 1790-1798.	3.8	69
21	The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. Annals of the Rheumatic Diseases, 2006, 65, 81-86.	0.9	66
22	Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Annals of the Rheumatic Diseases, 2006, 65, 109-111.	0.9	64
23	The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology. Clinical Reviews in Allergy and Immunology, 2012, 43, 256-264.	6.5	64
24	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature. Autoimmunity Reviews, 2011, 10, 679-684.	5.8	58
25	Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. British Journal of Rheumatology, 2005, 44, 95-99.	2.3	55
26	Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Annals of the Rheumatic Diseases, 2020, 79, 587-594.	0.9	52
27	Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Research and Therapy, 2009, 11, R17.	3 . 5	51
28	Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Seminars in Arthritis and Rheumatism, 2019, 49, 396-404.	3.4	50
29	Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clinical Rheumatology, 2007, 26, 1111-1118.	2.2	47
30	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology, 2020, 59, 1574-1580.	1.9	47
31	Enfermedad relacionada con IgG4: revisión concisa de la literatura. ReumatologÃa ClÃnica, 2017, 13, 160-166.	0.5	46
32	Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus, 2007, 16, 366-373.	1.6	45
33	Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With Endâ€Stage Renal Disease Due to Lupus Nephritis. Arthritis Care and Research, 2015, 67, 1453-1462.	3.4	45
34	Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. Immunologic Research, 2013, 56, 287-292.	2.9	43
35	Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. Arthritis Research and Therapy, 2009, 11, R135.	3.5	38
36	Effects of Smoking on Disease Activity and Radiographic Progression in Early Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2536-2539.	2.0	38

#	Article	IF	CITATIONS
37	Sarcoidosis pulmonar inducida por antagonistas del factor de necrosis tumoral en la artritis reumatoide: presentaci \tilde{A}^3 n de un caso y revisi \tilde{A}^3 n de la literatura m \tilde{A} ©dica. Archivos De Bronconeumologia, 2011, 47, 208-212.	0.8	38
38	Camptocormia as a clinical manifestation of mitochondrial myopathy. Clinical Rheumatology, 2007, 26, 1017-1019.	2.2	37
39	Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. Journal of the American Academy of Dermatology, 2013, 69, 19-24.	1.2	36
40	B-cell depleting agents for ANCA vasculitides: A new therapeutic approach. Autoimmunity Reviews, 2012, 11, 646-652.	5.8	34
41	Relapsing Catastrophic Antiphospholipid Syndrome Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses. Seminars in Arthritis and Rheumatism, 2013, 42, 417-423.	3.4	34
42	Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. Current Topics in Medicinal Chemistry, 2013, 13, 760-773.	2.1	34
43	Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and –negative rheumatoid arthritis patients. Arthritis Research and Therapy, 2013, 15, R182.	3.5	34
44	Infiltrating CD16+ Are Associated with a Reduction in Peripheral CD14+CD16++ Monocytes and Severe Forms of Lupus Nephritis. Autoimmune Diseases, 2016, 2016, 1-7.	0.6	32
45	Palindromic Rheumatism with Positive Anticitrullinated Peptide/Protein Antibodies Is Not Synonymous with Rheumatoid Arthritis. A Longterm Followup Study. Journal of Rheumatology, 2012, 39, 1929-1933.	2.0	31
46	Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmunity Reviews, 2006, 6, 81-84.	5.8	30
47	Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmunity Reviews, 2006, 6, 68-71.	5.8	28
48	High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis. Medicine (United) Tj ETQq0 0 0 rgB1	Γ <u>(O</u> verloc	k 10 Tf 50 30
49	Catastrophic Antiphospholipid Syndrome. Clinics in Laboratory Medicine, 2013, 33, 391-400.	1.4	26
50	HMGB1 ⁺ microparticles present in urine are hallmarks of nephritis in patients with systemic lupus erythematosus. European Journal of Immunology, 2019, 49, 323-335.	2.9	26
51	Anti-Chromatin (Anti-Nucleosome) Antibodies. Lupus, 2006, 15, 408-411.	1.6	25
52	Catastrophic Antiphospholipid Syndrome: Lessons from the "CAPS Registry" A Tribute to the Late Josep Font. Annals of the New York Academy of Sciences, 2007, 1108, 448-456.	3.8	25
53	Pregnancy and Catastrophic Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2009, 36, 85-90.	6.5	25
54	Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?. Rheumatology, 2011, 50, 1523-1525.	1.9	23

#	Article	IF	CITATIONS
55	Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients. Lupus, 2018, 27, 637-646.	1.6	23
56	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Journal of Autoimmunity, 2021, 117, 102580.	6.5	23
57	Coeliac disease associated with systemic sclerosis. Annals of the Rheumatic Diseases, 2004, 63, 104-105.	0.9	21
58	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. Journal of Rheumatology, 2019, 46, 1299-1308.	2.0	21
59	Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. Autoimmunity Reviews, 2006, 6, 85-88.	5.8	20
60	Lung Sarcoidosis Induced by TNF Antagonists in Rheumatoid Arthritis: A Case Presentation and a Literature Review. Archivos De Bronconeumologia, 2011, 47, 208-212.	0.8	19
61	The Use of Chimeric Vimentin Citrullinated Peptides for the Diagnosis of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2011, 54, 7486-7492.	6.4	19
62	Accelerated nodulosis during methotrexate therapy in a patient with systemic lupus erythematosus and Jaccoud's arthropathy. British Journal of Rheumatology, 2004, 43, 1587-1588.	2.3	18
63	Is There Subclinical Synovitis in Patients with Palindromic Rheumatism in the Intercritical Period? A Clinical and Ultrasonographic Study According to Anticitrullinated Protein Antibody Status. Journal of Rheumatology, 2014, 41, 1650-1655.	2.0	16
64	Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations. Medicine (United States), 2018, 97, e11727.	1.0	14
65	Transferrina y ceruloplasmina en orina de pacientes con lupus eritematoso sistémico. ¿Son útiles para diferenciar pacientes con nefritis lúpica?. ReumatologÃa ClÃnica, 2020, 16, 17-23.	0.5	14
66	Retraso diagnóstico y terapéutico de la artritis reumatoide y su relación con dispositivos asistenciales en Catalunya. Estudio AUDIT. ReumatologÃa ClÃnica, 2016, 12, 146-150.	0.5	13
67	Letter to the Editor. Lupus, 2003, 12, 866-869.	1.6	12
68	Macroscopic features of knee synovitis in early untreated Behçet disease and psoriatic arthritis. Clinical Rheumatology, 2009, 28, 1053-1057.	2.2	12
69	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. Antibodies, 2016, 5, 18.	2.5	12
70	A comparative study on clinical and serological characteristics between patients with rhupus and those with systemic lupus erythematosus and rheumatoid arthritis. Lupus, 2020, 29, 1216-1226.	1.6	12
71	Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis. Clinical Rheumatology, 2021, 40, 1853-1859.	2.2	12
72	The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis. JCI Insight, 2022, 7, .	5.0	11

#	Article	IF	Citations
73	Recurrent Pulmonary Thromboembolism in a Patient with Systemic Lupus Erythematosus and HIV-1 Infection Associated with the Presence of Antibodies to Prothrombin: A Case Report. Clinical Infectious Diseases, 2005, 41, e89-e92.	5.8	9
74	Organ Damage and Quality of Life in Antiphospholipid Syndrome. Current Rheumatology Reports, 2016, 18, 7.	4.7	9
75	Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?. Journal of Rheumatology, 2020, 47, 652-657.	2.0	9
76	Recurrent congenital heart block in neonatal lupus. Clinical Rheumatology, 2007, 26, 1161-1163.	2,2	8
77	Spleen tyrosine kinase inhibitors—novel therapies for RA?. Nature Reviews Rheumatology, 2011, 7, 134-136.	8.0	8
78	Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097813.	2.7	8
79	Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. Rheumatology, 2021, 60, 667-674.	1.9	8
80	Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy. Israel Medical Association Journal, 2006, 8, 513-4.	0.1	8
81	Partial HELLP syndrome in pregnancy complicated by recurrent deep vein thromboses and palmar skin lesions in a patient with prothrombin gene 20210a mutation and antiphospholipid antibodies: an unusual case. Clinical Rheumatology, 2008, 27, 245-248.	2.2	7
82	Antibodies against \hat{l}^2 -fibrin synthetic peptides: A study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients. European Journal of Medicinal Chemistry, 2011, 46, 1095-1102.	5.5	6
83	Valoración larÃngea mediante videolaringoestroboscopia en pacientes con artritis reumatoide. ReumatologÃa ClAnica, 2014, 10, 32-36.	0.5	6
84	Proliferative lupus nephritis in a patient with systemic lupus erythematosus and longstanding secondary amyloid nephropathy. Clinical Rheumatology, 2009, 28, 95-97.	2.2	5
85	Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome?. Lupus, 2013, 22, 754-755.	1.6	5
86	Laryngeal Assessment by Videolaryngostroboscopy in Patients With Rheumatoid Arthritis. ReumatologÃa ClÃnica (English Edition), 2014, 10, 32-36.	0.3	5
87	Papel de la vÃa de señalización del TWEAK/Fn14 en la nefritis lúpica y otros escenarios clÃnicos. Nefrologia, 2017, 37, 118-125.	0.4	5
88	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. RMD Open, 2020, 6, e001355.	3.8	5
89	Etanercept en pacientes con artritis reumatoide y escasa respuesta terapéutica a infliximab. Medicina ClÃnica, 2004, 122, 321-324.	0.6	5
90	Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. Journal of Clinical & Cellular Immunology, 2013, 04, 179.	1.5	5

#	Article	IF	CITATIONS
91	The Spectrum of Rheumatic Diseases. Handbook of Systemic Autoimmune Diseases, 2018, 15, 1-13.	0.1	4
92	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. European Journal of Internal Medicine, 2022, 99, 19-21.	2.2	4
93	Osteonecrosis múltiple. Patogénesis, caracterÃsticas clÃnicas y tratamiento. Seminarios De La Fundaciâ^šâ‰¥n Espaâ^šÂ±ola De Reumatologâ^šâ‰a, 2007, 8, 185-192.	0.1	3
94	Chapter 1 History, Classification, and Subsets of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2009, , $1-11$.	0.1	3
95	Skeletal Involvement in Antiphospholipid Syndrome. Current Rheumatology Reviews, 2010, 6, 25-31.	0.8	3
96	Prolonged Remission in SLE Revisited: An Old Wine in a New Bottle. Journal of Rheumatology, 2014, 41, 1728-1731.	2.0	3
97	What impact do race and ethnicity have on lupus mortality?. International Journal of Clinical Rheumatology, 2015, 10, 223-226.	0.3	3
98	History, Classification, and Subsets of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017 , , $1\text{-}16$.	0.1	3
99	Antinuclear antibodies mitotic patterns and their clinical associations. Annals of the Rheumatic Diseases, 2020, 79, e63-e63.	0.9	3
100	Design of an algorithm for the diagnostic approach of patients with joint pain. Clinical Rheumatology, 2021, 40, 1581-1591.	2.2	3
101	High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study. Diagnostics, 2022, 12, 182.	2.6	3
102	Sacral stress fracture as a cause of gluteal artery injury: An unusual complication of a common fracture. Joint Bone Spine, 2008, 75, 239-241.	1.6	2
103	Poliautoinmunidad en sÃndrome de Sjögren. Revista Colombiana De ReumatologÃa, 2020, 27, 58-66.	0.1	2
104	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
105	Diagnosis and treatment of articular manifestations of systemic lupus erythematosus. Revista Colombiana De ReumatologÃa, 2021, 28, 90-100.	0.1	2
106	"Catastrophic―Antiphospholipid Syndrome. Mayo Clinic Proceedings, 2003, 78, 519.	3.0	1
107	Dementia associated with antiphospholipid antibodies: reply. Rheumatology, 2006, 45, 242-243.	1.9	1
108	Overrepresentation of Elderly Subjects in a Populationâ€Based Study of Antiphospholipid Syndrome: Comment on the Article by Duarteâ€GarcÃa et al. Arthritis and Rheumatology, 2019, 71, 1768-1769.	5.6	1

#	Article	IF	Citations
109	THU0683â€COVERAGE, PREDICTORS OF VACCINATION AND FREQUENCY OF SEVERE INFECTIONS DUE TO STREPTOCOCCUS PNEUMONIAE IN A COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WITHIN AN EIGHTEEN-YEAR PERIOD., 2019, , .		1
110	Anti C1q antibodies. A promising biomarker for cocaine-levamisole induced vasculitis. ReumatologÃa ClÃnica, 2019, 15, e66-e67.	0.5	1
111	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	1.6	1
112	Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 2665-2672.	2.2	1
113	Controversies in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2022, 28, e651-e658.	0.9	1
114	Rheumatoid arthritis patients "al nostro cuore― European Journal of Internal Medicine, 2022, 96, 46-48.	2,2	1
115	Chapter 12 Antiphospholipid Syndrome Associated with Malignancies. Handbook of Systemic Autoimmune Diseases, 2009, , 149-154.	0.1	0
116	Correlación entre la actividad clÃnica por DAS-28 y ecografÃa en pacientes con artritis reumatoide. Revista Colombiana De ReumatologÃa, 2016, 23, 159-169.	0.1	0
117	Antiphospholipid Syndrome Associated With Malignancies. Handbook of Systemic Autoimmune Diseases, 2017, 12, 181-191.	0.1	0
118	AB0403â€PREDICTORS OF PERSISTENCE OF BIOLOGIC DRUG STEP-DOWN STRATEGIES IN INFLAMMATORY ARTHRITIS: A LONGITUDINAL STUDY IN CLINICAL PRACTICE WITH A LONG FOLLOW-UP. , 2019, , .		0
119	FRIO591â€RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES FROM TWO REFERRAL CENTRES. , 2019, , .		0
120	AB0511â€A COMPARATIVE STUDY ON CLINICAL AND SEROLOGICAL CHARACTERISTICS BETWEEN PATIENTS W RHUPUS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	ЛТН	0
121	Anti C1q antibodies. A promising biomarker for cocaine-levamisole induced vasculitis. ReumatologÃa ClÃnica (English Edition), 2019, 15, e66-e67.	0.3	0
122	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. Rheumatology, 2020, 59, e165-e168.	1.9	0
123	Coexistence of antiphospholipid syndrome and cryoglobulinemia in a patient with rheumatoid arthritis. Clinical Rheumatology, 2020, 39, 2833-2835.	2.2	0
124	Expanding diagnostic approach in patients with osteonecrosis. Arthritis Research and Therapy, 2021, 23, 150.	3.5	0
125	Interstitial lung disease and rheumatoid arthritis. Handbook of Systemic Autoimmune Diseases, 2022, , 21-40.	0.1	0
126	OA01â€fSafety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Rheumatology, 2022, 61, .	1.9	0

#	Article	lF	CITATIONS
127	Bilateral striopallidal calcinosis secondary to systemic lupus erythematosus. Radiology Case Reports, 2022, 17, 2257-2261.	0.6	O